Compare Biogen Inc (BIIB) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Prospect Capital Corporation — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Prospect Capital Corporation trades at $2.27 (market cap $1.14B). The key difference: Biogen Inc is far larger — about 24.9× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 22.03% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PSEC | |
|---|---|---|
Market Cap | $28.34B | $1.14B |
Sector | Health | Financials |
52-Week High | $216.63 | $3.47 |
52-Week Low | $122.68 | $2.15 |
Enterprise Value | $30.62B | — |
Dividend Yield | — | 22.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
PSEC trades at $2.25, down 0.44% recently, with a bearish technical signal and neutral oscillators. The company shows mixed fundamentals with a low P/B of 0.39 and consistent earnings beats in recent quarters, but negative revenue of -$407M and net income margin of -495.94% for 2025 highlight financial stress. Recent news includes a new investment in ShipOffers and ongoing dividend payments, though sentiment is cautious amid a deep discount to NAV.
The outlook remains challenging due to persistent negative revenue and high yield risks, but the valuation discount and earnings beats offer potential for value investors. Key risks include further NAV erosion and dividend sustainability, while institutional sentiment is divided with 25% buy ratings against 55% hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
